India Immune-Oncology Drugs Market Size Share Trends Forecast 2027

SEATTLE - Jan. 11, 2021 - PRLog -- India Immune-Oncology Drugs Market, By Drug Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, and Cancer Vaccines) and By Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, and Others) was valued at US$ 172.8 million in 2018 and is projected to exhibit a CAGR of 13.1% over the forecast period (2018 - 2026).

Increasing cancer research, new product launches, sales and marketing approvals, and rising number of development programs are major factors expected to drive growth of the India immune-oncology drugs market. Various organizations are focused on launching new products to aid India immune-oncology drugs market to gain fair share in the market.

Furthermore, some companies are engaged in receiving sales and marketing approvals from regulatory bodies of India to import their products, which can further increase India immune-oncology drugs market size. For instance, in June 2018, AstraZeneca Pharma India Limited received Import & Market permission for Durvalumab (Imfinzi) in India.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/india-immune-oncology-drugs-market-2631

Browse 38 Market Data Tables and 21 Figures spread through 162 Pages and in-depth TOC on "India immune-oncology drugs market, By Drug Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, and Cancer Vaccines) and By Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, and Others)- Global Forecast to 2026"

AstraZeneca Plc is engaged in creating awareness among the Indian community, in order to increase its market share in India. For instance, in February 2018, AstraZeneca Pharma India Limited and Indian Cancer Society launched a nationwide cancer awareness initiative – Cancer Screening for Women. Under this program, free, specialized cancer-screening was conducted across the country for women from underprivileged families.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2631

Key Takeaways of the India Immune-Oncology Drugs Market:

India immune-oncology drugs market is expected to expand at a CAGR of 13.1% during the forecast period (2018–2026), owing to increasing research & development and demand for genomic and repertoire sequencing-based research.

Major players operating in India immune-oncology drugs market include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories Ltd., Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company,

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2631